Improvement of freezing platelet storage

A technology for platelets and whole blood, applied in the direction of medical raw materials derived from mammals, etc., can solve the problems of platelets cannot be transfused into platelets, and platelets cannot be stored for a long time, and achieve the effects of avoiding bacterial reproduction, good hemostatic function, and good curative effect.

Inactive Publication Date: 2007-08-08
北京帕拉莱特生物医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In order to overcome the following technical problems in the preservation of platelets in the prior art: platelet...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Improvement of freezing platelet storage
  • Improvement of freezing platelet storage
  • Improvement of freezing platelet storage

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0066] Preparation Example 1 Selection of galactose uridine diphosphate concentration

[0067] Platelet counts 1 hour after infusion are described corresponding to the concentration of added galactose uridine diphosphate. The blue line represents platelets stored at 0°C, and the red line represents platelets stored at -80°C. Test results, see Figure 1. When the concentration of galactose uridine diphosphate is 50μM, the average (SEM) number in the blood is greater than 75×10 9 / L; when the concentration of galactose uridine diphosphate was 300 μM, the average (SEM) number in the blood was 98.3×10 9 / L; when the concentration of galactose uridine diphosphate was greater than 300 μM, the average (SEM) number in the blood was 98×10 9 / L or so, there is no obvious change. Experiments show that the concentration of galactose uridine diphosphate is preferably 50 μM-50 mM, more preferably 100 μM-3 mM, and most preferably 300 μM.

preparation example 2

[0068] Preparation Example 2 Preparation of Platelet Concentrate

[0069] Processing of whole blood:

[0070] Human whole blood was obtained from healthy volunteers. The blood product was equally divided into 5 aliquots: two of them were treated with 300 [mu]M galactose uridine diphosphate for 30 minutes at 37[deg.]C.

[0071] Procurement of Platelet Concentrate: Platelet concentrates are prepared from blood collected into the ACD. Add 0.8 μM prostaglandin I 2 Then, it was collected by centrifugation at 900×g for 15 minutes.

[0072] Processing of Platelet Concentrate:

[0073] Platelet concentrate obtained from whole blood without galactose uridine diphosphate:

[0074] Sample C1 was stored at room temperature (fresh platelets);

[0075] Sample C2, stored at 0°C for 2 hours

[0076] For sample C3, 5% (final concentration) of DMSO was added, and then stored at -80°C for 2 hours.

[0077] Platelet concentrate obtained by adding galactose uridine diphosphate whole blood:...

preparation example 3

[0081] Preparation Example 3 Preparation of Platelet Suspension

[0082] Acquisition of platelet suspension: the platelet concentrate obtained as described above was centrifuged at 1500×g for 10 minutes to remove the supernatant to obtain platelet pellet, and then washed with CGS buffer (13mM sodium citrate, 30mM D-glucose, 120mM sodium chloride ) wash 2 times. The eluted platelets were resuspended in Tyrode's buffer (8.19 g sodium chloride, 0.20 g potassium chloride, 1.01 g sodium bicarbonate, 0.055 g sodium dihydrogen phosphate, 0.991 g D-glucose) to obtain a platelet suspension.

[0083] Processing of platelet suspension:

[0084] Platelet suspension obtained without adding galactose uridine diphosphate whole blood:

[0085]Sample S1 was stored at room temperature;

[0086] Sample S2 was stored at 0°C for 2 hours;

[0087] Sample S3 was added with 5% (final concentration) DMSO, and then stored at -80°C for 2 hours.

[0088] Platelet suspension obtained by adding galact...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method for processing and storing platelet product, which adds uridine diphosphate galactose into the platelet product to improve the platelet circulation function in the body, to effectively improve the platelet number after blood transfusion. The inventive frozen platelet has better hemostatic effect than fresh platelet, which can be used to stop bleeding of emergence patient and transfuse platelet.

Description

technical field [0001] The present invention relates to a method for improving the storage stability of blood products such as frozen platelet concentrates and preventing the removal of frozen platelets transfused into the body. In particular, the addition of galactose uridine diphosphate to platelet concentrates prior to freezing provides a means of prolonging the survival of these preparations and their inhibition of post-infusion clearance. Background technique [0002] In recent years, the status of platelets in component blood transfusion has become more and more important. It is mainly used for patients with decreased platelet count or abnormal function accompanied with bleeding tendency or manifestations, and dilutional thrombocytopenia (platelets <50×10) caused by massive blood transfusion. 9 / L) with bleeding and preventive platelet transfusion. And the proportion of platelet transfusion is significantly increasing year by year. [0003] As far as the current d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/12A61K35/19
Inventor 田菲
Owner 北京帕拉莱特生物医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap